RxDoctor Payments Data

Richard Tisovec, MD

Internal Medicine · Greensboro, NCNPI 1306863741

Payments from drug & device makers

$17,179in general payments, 2019–2025

Across 647 payments — averaging $26.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • GSK$1K
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$1751%
  • Speaking & faculty fees$2071%
  • Food & beverage$16,79298%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca37$1,936
Amgen64$1,680
Novo Nordisk47$1,563
Lilly USA, LLC58$1,486
AbbVie(2 entities)61$1,158
GSK31$1,044
Pfizer38$667
Medtronic(2 entities)9$582
Cequr Corporation4$470
Johnson & Johnson13$455
Sanofi-aventis U.S. LLC21$450
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$433
Esperion Therapeutics, Inc.11$376
Exact Sciences10$350
Novartis18$347
Abbott21$336
Bayer9$303
Boehringer Ingelheim20$294
Amarin Pharma, Inc.10$240
Otsuka America Pharmaceutical, Inc.8$181
Astellas Pharma US Inc13$171
Radius Health, Inc.10$164
Mylan Specialty L.p.3$164
Eisai Inc.2$136
Sunovion Pharmaceuticals Inc.10$135
Phathom Pharmaceuticals, Inc.1$125
Tandem Diabetes Care, Inc.2$125
Takeda Pharmaceuticals U.S.A., Inc.10$124
Mallinckrodt Hospital Products Inc.1$120
Merck9$117
Sumitomo Pharma America, Inc.6$114
Sanofi1$110
Dexcom, Inc.7$108
Amneal Pharmaceuticals LLC7$104
Mannkind Corporation6$78
Biohaven Pharmaceuticals, Inc.5$74
Lifescan, Inc.4$58
Madrigal Pharmaceuticals2$54
E.r. Squibb & Sons, L.L.C.4$52
Xeris Pharmaceuticals, Inc.4$52
Genentech USA, Inc.3$49
Nestle Healthcare Nutrition Inc.3$40
Daiichi Sankyo Inc.2$40
Sanofi Pasteur Inc.2$39
Biohaven Pharmaceutical Holding Company Ltd.2$38
Ironwood Pharmaceuticals, Inc3$34
Antares Pharma, Inc.2$33
Regeneron Healthcare Solutions, Inc.2$33
Nevro Corp.2$33
Aimmune Therapeutics, Inc.1$30
IBSA Pharma Inc.2$29
Vanda Pharmaceuticals Inc.1$24
Viatris Specialty LLC1$21
Avanir Pharmaceuticals, Inc.1$20
ARS Pharmaceuticals Operations, Inc.1$20
Seqirus USA Inc1$20
Idorsia Pharmaceuticals US Inc1$19
Irhythm Technologies, Inc.1$19
Corcept Therapeutics1$19
Senseonics, Incorporated1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,179 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$147,703
Medicare patients
227
Services billed
3,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin142$151,021
OzempicSemaglutide98$113,198
EliquisApixaban47$58,066
FarxigaDapagliflozin Propanediol51$56,876
XareltoRivaroxaban27$40,253
Tresiba Flextouch U-200Insulin Degludec25$31,478
Bydureon BciseExenatide Microspheres27$26,650
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$22,188
TradjentaLinagliptin20$22,030
JanuviaSitagliptin Phosphate22$21,898
Synjardy XrEmpagliflozin/Metformin Hcl21$21,268
InvokanaCanagliflozin12$20,620
Jentadueto XrLinagliptin/Metformin Hcl18$19,520
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$18,852
SynjardyEmpagliflozin/Metformin Hcl16$18,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Jentadueto Xr, Synjardy$294$245,582229 claims
Novo NordiskOzempic, Novolog$1,563$118,313115 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,936$72,01566 claims
PfizerEliquis, Paxlovid$667$71,84989 claims
Johnson & JohnsonXarelto, Invokana$455$60,87439 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,044$36,01556 claims
MerckJanuvia$117$21,89822 claims
Astellas Pharma US IncMyrbetriq$171$14,15825 claims
AbbVieSynthroid$1,158$8,40686 claims
Esperion Therapeutics, Inc.Nexletol$376$4,70412 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$104$4,384382 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →